Literature DB >> 32270167

Coordination chemistry of [Y(pypa)]- and comparison immuno-PET imaging of [44Sc]Sc- and [86Y]Y-pypa-phenyl-TRC105.

Lily Li1, María de Guadalupe Jaraquemada-Peláez, Eduardo Aluicio-Sarduy, Xiaozhu Wang, Todd E Barnhart, Weibo Cai, Valery Radchenko, Paul Schaffer, Jonathan W Engle, Chris Orvig.   

Abstract

Both scandium-44 and yttrium-86 are popular PET isotopes with appropriate half-lives for immuno-positron emission tomography (immuno-PET) imaging. Herein, a new bifunctional H4pypa ligand, H4pypa-phenyl-NCS, is synthesized, conjugated to a monoclonal antibody, TRC105, and labeled with both radionuclides to investigate the long-term in vivo stability of each complex. While the 44Sc-labeled radiotracer exhibited promising pharmacokinetics and stability in 4T1-xenograft mice (n = 3) even upon prolonged interactions with blood serum proteins, the progressive bone uptake of the 86Y-counterpart indicated in vivo demetallation, obviating H4pypa as a suitable chelator for Y3+ ion in vivo. The solution chemistry of [natY(pypa)]- was studied in detail and the complex found to be thermodynamically stable in solution with a pM value 22.0, ≥3 units higher than those of the analogous DOTA- and CHX-A''-DTPA-complexes; the 86Y-result in vivo was therefore most unexpected. To explore further this in vivo lability, Density Functional Theory (DFT) calculation was performed to predict the geometry of [Y(pypa)]- and the results were compared with those for the analogous Sc- and Lu-complexes; all three adopted the same coordination geometry (i.e. distorted capped square antiprism), but the metal-ligand bonds were much longer in [Y(pypa)]- than in [Lu(pypa)]- and [Sc(pypa)]-, which could indicate that the size of the binding cavity is too small for the Y3+ ion, but suitable for both the Lu3+ and Sc3+ ions. Considered along with results from [86Y][Y(pypa-phenyl-TRC105)], it is noted that when matching chelators with radionuclides, chemical data such as the thermodynamic stability and in vitro inertness, albeit useful and necessary, do not always translate to in vivo inertness, especially with the prolonged blood circulation of the radiotracer bound to a monoclonal antibody. Although H4pypa is a nonadentate chelator, which theoretically matches the coordination number of the Y3+ ion, we show herein that its binding cavity, in fact, favors smaller metal ions such as Sc3+ and Lu3+ and further exploitation of the Sc-pypa combination is desired.

Entities:  

Year:  2020        PMID: 32270167      PMCID: PMC7222037          DOI: 10.1039/d0dt00437e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  56 in total

1.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein.

Authors:  A W Vermeer; W Norde
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

Review 2.  Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory.

Authors:  Suresh C Srivastava
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

3.  Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc.

Authors:  Marek Pruszyński; Agnieszka Majkowska-Pilip; Natalia S Loktionova; Elisabeth Eppard; Frank Roesch
Journal:  Appl Radiat Isot       Date:  2012-03-18       Impact factor: 1.513

4.  Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Authors:  Sangeeta Ray Banerjee; Catherine A Foss; Mrudula Pullambhatla; Yuchuan Wang; Senthamizhchelvan Srinivasan; Robert F Hobbs; Kwamena E Baidoo; Martin W Brechbiel; Sridhar Nimmagadda; Ronnie C Mease; George Sgouros; Martin G Pomper
Journal:  J Nucl Med       Date:  2015-02-26       Impact factor: 10.057

5.  Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs.

Authors:  P Gans; A Sabatini; A Vacca
Journal:  Talanta       Date:  1996-10       Impact factor: 6.057

6.  The role of the capping bond effect on pyclen natY3+/90Y3+ chelates: full control of the regiospecific N-functionalization makes the difference.

Authors:  Mariane Le Fur; Maryline Beyler; Enikő Molnár; Olivier Fougère; David Esteban-Gómez; Gyula Tircsó; Carlos Platas-Iglesias; Nicolas Lepareur; Olivier Rousseaux; Raphaël Tripier
Journal:  Chem Commun (Camb)       Date:  2017-08-24       Impact factor: 6.222

7.  A highly effective bifunctional ligand for radioimmunotherapy applications.

Authors:  Hyun-Soon Chong; Hyun A Song; Chi Soo Kang; Thien Le; Xiang Sun; Mamta Dadwal; Hyunbeom Lee; Xiaoli Lan; Yunwei Chen; Anzhi Dai
Journal:  Chem Commun (Camb)       Date:  2011-04-05       Impact factor: 6.222

8.  Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates.

Authors:  T J McMurry; C G Pippin; C Wu; K A Deal; M W Brechbiel; S Mirzadeh; O A Gansow
Journal:  J Med Chem       Date:  1998-08-27       Impact factor: 7.446

9.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

Review 10.  PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.

Authors:  Guus A M S van Dongen; Alex J Poot; Danielle J Vugts
Journal:  Tumour Biol       Date:  2012-01-21
View more
  1 in total

1.  Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine.

Authors:  Alex Rigby; George Firth; Charlotte Rivas; Truc Pham; Jana Kim; Andreas Phanopoulos; Luke Wharton; Aidan Ingham; Lily Li; Michelle T Ma; Chris Orvig; Philip J Blower; Samantha Y A Terry; Vincenzo Abbate
Journal:  Bioconjug Chem       Date:  2022-07-08       Impact factor: 6.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.